- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Patent holdings for IPC class C07D 403/14
Total number of patents in this class: 7725
10-year publication summary
576
|
525
|
558
|
547
|
600
|
639
|
616
|
634
|
700
|
176
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Merck Patent GmbH | 5909 |
167 |
Bristol-myers Squibb Company | 5080 |
163 |
Idemitsu Kosan Co., Ltd. | 3995 |
131 |
F. Hoffmann-La Roche AG | 7958 |
130 |
Novartis AG | 11238 |
126 |
Boehringer Ingelheim International GmbH | 4629 |
113 |
Janssen Pharmaceutica N.V. | 3839 |
104 |
Merck Sharp & Dohme LLC | 3689 |
94 |
Samsung Display Co., Ltd. | 30585 |
92 |
LG Chem, Ltd. | 17205 |
91 |
AstraZeneca AB | 3042 |
80 |
Gilead Sciences, Inc. | 1879 |
77 |
Achillion Pharmaceuticals, Inc. | 176 |
75 |
Hoffmann-La Roche Inc. | 3060 |
73 |
Pfizer Inc. | 3322 |
69 |
Vertex Pharmaceuticals Incorporated | 1581 |
65 |
Rigel Pharmaceuticals, Inc. | 613 |
65 |
Incyte Corporation | 918 |
64 |
Amgen Inc. | 3779 |
63 |
Takeda Pharmaceutical Company Limited | 2961 |
62 |
Other owners | 5821 |